Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMILI (norgestimate and ethinyl estradiol) by Aurobindo Pharma is • oral contraception cocs lower the risk of becoming pregnant primarily by suppressing ovulation. Approved for moderate acne vulgaris in females at least 15 years of age. First approved in 2016.
Drug data last refreshed 21h ago
• Oral Contraception COCs lower the risk of becoming pregnant primarily by suppressing ovulation.
Personalizing Mental Health Treatment for Youth and Families
Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
A Mentalization Based Prevention Program to Foster Well-Being and Mental Health in Pre-Adolescent Children and Their Families
Worked on MILI at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo